Comparative safety of sulfonylureas and the risk of sudden cardiac arrest and ventricular arrhythmia
Confounding Factors (Epidemiology)
Data Interpretation, Statistical
Outcome Assessment (Health Care)
Glyburide may be associated with a lower risk of SCA/VA than glipizide, consistent with a very small clinical trial suggesting that glyburide may reduce ventricular tachycardia and isolated ventricular premature complexes. This potential benefit must be contextualized by considering putative effects of different sulfonylureas on other cardiovascular end points, cerebrovascular end points, all-cause death, and hypoglycemia.